Advanced Prostate Cancer

Home » Advanced Prostate Cancer

Bipolar Androgen Therapy

Research hope for prostate cancer Pouring petrol on the fire can potentially reverse resistance to hormone treatments for prostate cancer, new research suggests. The counter-intuitive strategy called bipolar androgen therapy (BAT) involves boosting levels of the male hormone testosterone, which normally stimulates prostate cancer growth. In a small pilot study, scientists found that alternating high and low testosterone levels caused seven of 16 patients with resistant prostate cancer to go into remission. Read the article.

Bipolar Androgen Therapy Read More »

Advances in Prostate Cancer: 2014

The year 2014 has again provided important developments in the area of prostate cancer. New data and new treatments span the spectrum of prostate cancer management, from prevention and screening to optimal strategies for localized, locally advanced, and metastatic disease. Read the article.  (Free Medscape account required.)

Advances in Prostate Cancer: 2014 Read More »

Managing bone health in patients with prostate cancer

Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4): 7399-7403. Urologists have two scenarios where they have to address bone loss or increased risk of fractures in men with prostate cancer. In the first setting, a patient who has been started on androgen deprivation therapy may develop cancer-treatment-induced bone loss. In the second setting, a patient’s prostate cancer may have metastasized to the bone. This article describes six steps to manage bone health in patients diagnosed with prostate cancer

Managing bone health in patients with prostate cancer Read More »

Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa

Starting chemotherapy along with androgen deprivation therapy (ADT) in patients newly diagnosed with metastatic prostate cancer (mPCa) improved median overall survival by more than 13 months, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago. Read the article.

Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa Read More »

Combine treatment for moderate to high risk prostate cancer

Men with intermediate or high-risk localised prostate cancer should be given a combination of radical radiotherapy and androgen deprivation therapy, rather than radical radiotherapy or androgen deprivation therapy alone, recommends newly updated guidance [publications.nice.org.uk] from the National Institute of Health and Care Excellence (NICE), published today. Read the article.

Combine treatment for moderate to high risk prostate cancer Read More »

Castrate-resistant Prostate Cancer – Recent Advances in Therapy and Future Perspectives

Abstract For many years, few therapeutic options were available for the treatment of advanced prostate cancer. Recent advances in our understanding of the molecular biology of prostate cancer, particularly in the transition to castrate resistant disease, have led to the development of more potent and selective endocrine therapies. In addition, elucidation of the many factors in the bone microenvironment that promote the development and subsequent progression of skeletal metastases has led to the discovery of new bone-targeting agents that can delay the onset of skeletal related events and improve quality of life and survival. This review will highlight recently approved

Castrate-resistant Prostate Cancer – Recent Advances in Therapy and Future Perspectives Read More »

Evidence says less may be more when it comes to radiation for bone metastases

Patients enduring the excruciating pain of cancer that has spread to the bones are often given multiple doses of radiation. There is strong evidence, however, that one dose controls pain as effectively as 10 or more. In addition, one treatment is cheaper and far more convenient for patients who already have plenty on their minds. Read the Article.

Evidence says less may be more when it comes to radiation for bone metastases Read More »

Scroll to Top